Literature DB >> 24349962

Does physician continuity within a clinical trial increase retention and compliance among adolescent smokers?

A Lee Lewis1, Nathaniel Baker1, Matthew Carpenter1, Erin Klintworth1, Kevin M Gray1.   

Abstract

BACKGROUND: Retention and compliance are hurdles in many clinical trials designed for adolescents. Factors that may improve these issues in a challenging population may lead to increased data and power in much needed adolescent substance abuse research.
METHODS: Within a large-scale smoking cessation study for adolescents, physician continuity (PC) was examined to determine its effect on retention, compliance, and cessation.
RESULTS: In an analysis of 98 participants, participants with physician continuity throughout the study were more likely to attend more treatment visits and be medication compliant. It was also found that PC had no effect on participant smoking cessation.
CONCLUSIONS: It appears that PC may be one way to increase retention and compliance within an adolescent clinical trial, without interfering with the specific aim of the research study (in this case, smoking cessation).

Entities:  

Year:  2013        PMID: 24349962      PMCID: PMC3857140          DOI: 10.2174/2210676611303020011

Source DB:  PubMed          Journal:  Adolesc Psychiatry (Hilversum)        ISSN: 2210-6766


  20 in total

1.  A meta-analysis of teen cigarette smoking cessation.

Authors:  Steve Sussman; Ping Sun; Clyde W Dent
Journal:  Health Psychol       Date:  2006-09       Impact factor: 4.267

2.  The effectiveness of the Minnesota Model approach in the treatment of adolescent drug abusers.

Authors:  K C Winters; R D Stinchfield; E Opland; C Weller; W W Latimer
Journal:  Addiction       Date:  2000-04       Impact factor: 6.526

3.  Beyond quitting: predictors of teen smoking cessation, reduction and acceleration following a school-based intervention.

Authors:  Steven A Branstetter; Kimberly Horn; Geri Dino; Jianjun Zhang
Journal:  Drug Alcohol Depend       Date:  2008-09-19       Impact factor: 4.492

4.  Continuity of care and delivery of ambulatory services to children in community health clinics.

Authors:  A S O'Malley; C B Forrest
Journal:  J Community Health       Date:  1996-06

5.  Continuity of care and clinical effectiveness: outcomes following residential treatment for severe substance abuse.

Authors:  Greg A Greenberg; Robert A Rosenheck; Catherine L Seibyl
Journal:  Med Care       Date:  2002-03       Impact factor: 2.983

6.  Bupropion SR and contingency management for adolescent smoking cessation.

Authors:  Kevin M Gray; Matthew J Carpenter; Nathaniel L Baker; Karen J Hartwell; A Lee Lewis; D Walter Hiott; Deborah Deas; Himanshu P Upadhyaya
Journal:  J Subst Abuse Treat       Date:  2010-10-08

Review 7.  Does continuity of care improve patient outcomes?

Authors:  Michael D Cabana; Sandra H Jee
Journal:  J Fam Pract       Date:  2004-12       Impact factor: 0.493

8.  Randomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation.

Authors:  Myra L Muramoto; Scott J Leischow; Duane Sherrill; Eva Matthews; Louise J Strayer
Journal:  Arch Pediatr Adolesc Med       Date:  2007-11

9.  Treatment staff's continuity of care practices, patients' engagement in continuing care, and abstinence following outpatient substance-use disorder treatment.

Authors:  Jeanne A Schaefer; Alex H S Harris; Ruth C Cronkite; Patricia Turrubiartes
Journal:  J Stud Alcohol Drugs       Date:  2008-09       Impact factor: 2.582

10.  Significant reduction of repeat teen pregnancy in a comprehensive young parent program.

Authors:  H A Omar; A Fowler; K K McClanahan
Journal:  J Pediatr Adolesc Gynecol       Date:  2008-10       Impact factor: 1.814

View more
  1 in total

1.  Benefits and barriers to participating in longitudinal research of youth-onset type 2 diabetes: Results from the TODAY retention survey.

Authors:  Natalie Walders-Abramson; Barbara Anderson; Mary E Larkin; Nancy Chang; Elizabeth Venditti; Suzan Bzdick; Jeanie B Tryggestad; Kenny Tan; Mitchell E Geffner; Kathryn Hirst
Journal:  Clin Trials       Date:  2015-11-03       Impact factor: 2.486

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.